(ESAB) ESAB - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US29605J1060
Stock: Welding Consumables, Cutting Consumables, Welding Equipment, Software
Total Rating 40
Risk 76
Buy Signal -1.86
| Risk 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -35.56 |
| Character TTM | |
|---|---|
| Beta | 1.119 |
| Beta Downside | 0.659 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.55% |
| CAGR/Max DD | 1.04 |
EPS (Earnings per Share)
Revenue
Description: ESAB ESAB February 25, 2026
ESAB Corporation (NYSE: ESAB) designs, manufactures, and distributes welding and cutting consumables, equipment, and digital workflow solutions for a broad range of industries-including infrastructure, renewable energy, transportation, and life sciences-through a global network of distributors and direct sales teams.
In FY 2024 the company reported revenue of approximately $2.1 billion, an EBITDA margin of 12%, and operating cash flow of $250 million, while its renewable-energy segment grew 15% year-over-year, reflecting strong demand for hydrogen-related infrastructure projects.
Key sector drivers include a 4% annual increase in global infrastructure spending, accelerated adoption of automation and IoT in manufacturing, and rising construction of offshore wind and green-hydrogen facilities that boost demand for high-performance welding consumables.
For a deeper quantitative view, you might explore ValueRay’s analyst toolkit.
Headlines to watch out for
- Industrial gas and welding equipment demand impacts revenue
- Raw material price volatility affects profitability
- Infrastructure spending boosts fabrication equipment sales
- Currency fluctuations influence international earnings
- Competition from low-cost manufacturers pressures margins
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 226.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -3.05 > 1.0 |
| NWC/Revenue: 21.01% < 20% (prev 18.84%; Δ 2.17% < -1%) |
| CFO/TA 0.05 > 3% & CFO 260.6m > Net Income 226.8m |
| Net Debt (1.25b) to EBITDA (497.4m): 2.51 < 3 |
| Current Ratio: 1.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.9m) vs 12m ago 0.70% < -2% |
| Gross Margin: 35.54% > 18% (prev 0.38%; Δ 3.52k% > 0.5%) |
| Asset Turnover: 64.60% > 50% (prev 67.94%; Δ -3.34% > 0%) |
| Interest Coverage Ratio: 5.21 > 6 (EBITDA TTM 497.4m / Interest Expense TTM 79.3m) |
Altman Z'' 2.11
| A: 0.13 (Total Current Assets 1.26b - Total Current Liabilities 664.8m) / Total Assets 4.77b |
| B: 0.17 (Retained Earnings 800.8m / Total Assets 4.77b) |
| C: 0.09 (EBIT TTM 413.4m / Avg Total Assets 4.40b) |
| D: 0.10 (Book Value of Equity 261.2m / Total Liabilities 2.55b) |
| Altman-Z'' Score: 2.11 = BBB |
Beneish M -2.79
| DSRI: 1.18 (Receivables 451.3m/370.3m, Revenue 2.84b/2.74b) |
| GMI: 1.07 (GM 35.54% / 37.85%) |
| AQI: 1.02 (AQ_t 0.63 / AQ_t-1 0.62) |
| SGI: 1.04 (Revenue 2.84b / 2.74b) |
| TATA: -0.01 (NI 226.8m - CFO 260.6m) / TA 4.77b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of ESAB shares?
As of March 15, 2026, the stock is trading at USD 108.14 with a total of 356,676 shares traded.
Over the past week, the price has changed by -9.15%, over one month by -27.36%, over three months by -15.10% and over the past year by -15.23%.
Over the past week, the price has changed by -9.15%, over one month by -27.36%, over three months by -15.10% and over the past year by -15.23%.
Is ESAB a buy, sell or hold?
ESAB has received a consensus analysts rating of 3.91.
Therefore, it is recommended to buy ESAB.
- StrongBuy: 5
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the ESAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 147.2 | 36.1% |
| Analysts Target Price | 147.2 | 36.1% |
ESAB Fundamental Data Overview March 15, 2026
P/E Trailing = 26.2902
P/E Forward = 18.4502
P/S = 2.3501
P/B = 3.0221
P/EG = 1.1289
Revenue TTM = 2.84b USD
EBIT TTM = 413.4m USD
EBITDA TTM = 497.4m USD
Long Term Debt = 1.23b USD (from longTermDebt, last quarter)
Short Term Debt = 24.5m USD (from shortTermDebt, last quarter)
Debt = 1.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (from netDebt column, last quarter)
Enterprise Value = 7.93b USD (6.68b + Debt 1.43b - CCE 185.9m)
Interest Coverage Ratio = 5.21 (Ebit TTM 413.4m / Interest Expense TTM 79.3m)
EV/FCF = 37.17x (Enterprise Value 7.93b / FCF TTM 213.3m)
FCF Yield = 2.69% (FCF TTM 213.3m / Enterprise Value 7.93b)
FCF Margin = 7.50% (FCF TTM 213.3m / Revenue TTM 2.84b)
Net Margin = 7.98% (Net Income TTM 226.8m / Revenue TTM 2.84b)
Gross Margin = 35.54% ((Revenue TTM 2.84b - Cost of Revenue TTM 1.83b) / Revenue TTM)
Gross Margin QoQ = 30.47% (prev 37.00%)
Tobins Q-Ratio = 1.66 (Enterprise Value 7.93b / Total Assets 4.77b)
Interest Expense / Debt = 1.25% (Interest Expense 17.9m / Debt 1.43b)
Taxrate = 19.79% (12.7m / 64.1m)
NOPAT = 331.6m (EBIT 413.4m * (1 - 19.79%))
Current Ratio = 1.90 (Total Current Assets 1.26b / Total Current Liabilities 664.8m)
Debt / Equity = 0.66 (Debt 1.43b / totalStockholderEquity, last quarter 2.17b)
Debt / EBITDA = 2.51 (Net Debt 1.25b / EBITDA 497.4m)
Debt / FCF = 5.85 (Net Debt 1.25b / FCF TTM 213.3m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.15% (Net Income 226.8m / Total Assets 4.77b)
RoE = 10.98% (Net Income TTM 226.8m / Total Stockholder Equity 2.07b)
RoCE = 12.54% (EBIT 413.4m / Capital Employed (Equity 2.07b + L.T.Debt 1.23b))
RoIC = 10.21% (NOPAT 331.6m / Invested Capital 3.25b)
WACC = 8.44% (E(6.68b)/V(8.11b) * Re(10.04%) + D(1.43b)/V(8.11b) * Rd(1.25%) * (1-Tc(0.20)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.53%
[DCF] Terminal Value 79.09% ; FCFF base≈249.4m ; Y1≈292.6m ; Y5≈443.6m
[DCF] Fair Price = 93.77 (EV 6.94b - Net Debt 1.25b = Equity 5.69b / Shares 60.7m; r=8.44% [WACC]; 5y FCF grow 18.42% → 2.90% )
EPS Correlation: 80.97 | EPS CAGR: 3.89% | SUE: 0.0 | # QB: 0
Revenue Correlation: 69.04 | Revenue CAGR: 2.89% | SUE: 2.79 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.49 | Chg7d=+0.000 | Chg30d=-0.045 | Revisions Net=-4 | Analysts=9
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=-0.002 | Chg30d=-0.126 | Revisions Net=-6 | Growth EPS=+10.4% | Growth Revenue=+8.2%
EPS next Year (2027-12-31): EPS=6.48 | Chg7d=-0.002 | Chg30d=-0.213 | Revisions Net=-1 | Growth EPS=+11.4% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: -0.67 (1 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 10.0% - Earnings Yield 3.8%)
[Growth] Growth Spread = +3.8% (Analyst 10.1% - Implied 6.2%)
P/E Forward = 18.4502
P/S = 2.3501
P/B = 3.0221
P/EG = 1.1289
Revenue TTM = 2.84b USD
EBIT TTM = 413.4m USD
EBITDA TTM = 497.4m USD
Long Term Debt = 1.23b USD (from longTermDebt, last quarter)
Short Term Debt = 24.5m USD (from shortTermDebt, last quarter)
Debt = 1.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.25b USD (from netDebt column, last quarter)
Enterprise Value = 7.93b USD (6.68b + Debt 1.43b - CCE 185.9m)
Interest Coverage Ratio = 5.21 (Ebit TTM 413.4m / Interest Expense TTM 79.3m)
EV/FCF = 37.17x (Enterprise Value 7.93b / FCF TTM 213.3m)
FCF Yield = 2.69% (FCF TTM 213.3m / Enterprise Value 7.93b)
FCF Margin = 7.50% (FCF TTM 213.3m / Revenue TTM 2.84b)
Net Margin = 7.98% (Net Income TTM 226.8m / Revenue TTM 2.84b)
Gross Margin = 35.54% ((Revenue TTM 2.84b - Cost of Revenue TTM 1.83b) / Revenue TTM)
Gross Margin QoQ = 30.47% (prev 37.00%)
Tobins Q-Ratio = 1.66 (Enterprise Value 7.93b / Total Assets 4.77b)
Interest Expense / Debt = 1.25% (Interest Expense 17.9m / Debt 1.43b)
Taxrate = 19.79% (12.7m / 64.1m)
NOPAT = 331.6m (EBIT 413.4m * (1 - 19.79%))
Current Ratio = 1.90 (Total Current Assets 1.26b / Total Current Liabilities 664.8m)
Debt / Equity = 0.66 (Debt 1.43b / totalStockholderEquity, last quarter 2.17b)
Debt / EBITDA = 2.51 (Net Debt 1.25b / EBITDA 497.4m)
Debt / FCF = 5.85 (Net Debt 1.25b / FCF TTM 213.3m)
Total Stockholder Equity = 2.07b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.15% (Net Income 226.8m / Total Assets 4.77b)
RoE = 10.98% (Net Income TTM 226.8m / Total Stockholder Equity 2.07b)
RoCE = 12.54% (EBIT 413.4m / Capital Employed (Equity 2.07b + L.T.Debt 1.23b))
RoIC = 10.21% (NOPAT 331.6m / Invested Capital 3.25b)
WACC = 8.44% (E(6.68b)/V(8.11b) * Re(10.04%) + D(1.43b)/V(8.11b) * Rd(1.25%) * (1-Tc(0.20)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.53%
[DCF] Terminal Value 79.09% ; FCFF base≈249.4m ; Y1≈292.6m ; Y5≈443.6m
[DCF] Fair Price = 93.77 (EV 6.94b - Net Debt 1.25b = Equity 5.69b / Shares 60.7m; r=8.44% [WACC]; 5y FCF grow 18.42% → 2.90% )
EPS Correlation: 80.97 | EPS CAGR: 3.89% | SUE: 0.0 | # QB: 0
Revenue Correlation: 69.04 | Revenue CAGR: 2.89% | SUE: 2.79 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.49 | Chg7d=+0.000 | Chg30d=-0.045 | Revisions Net=-4 | Analysts=9
EPS current Year (2026-12-31): EPS=5.82 | Chg7d=-0.002 | Chg30d=-0.126 | Revisions Net=-6 | Growth EPS=+10.4% | Growth Revenue=+8.2%
EPS next Year (2027-12-31): EPS=6.48 | Chg7d=-0.002 | Chg30d=-0.213 | Revisions Net=-1 | Growth EPS=+11.4% | Growth Revenue=+4.5%
[Analyst] Revisions Ratio: -0.67 (1 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 10.0% - Earnings Yield 3.8%)
[Growth] Growth Spread = +3.8% (Analyst 10.1% - Implied 6.2%)